Seaport Res Ptn Analysts Raise Earnings Estimates for HIMS

Hims & Hers Health, Inc. (NYSE:HIMS) – Analysts at Seaport Res Ptn upped their Q1 2025 EPS estimates for Hims & Hers Health in a research note issued on Monday, February 24th. Seaport Res Ptn analyst A. Kessler now expects that the company will post earnings of $0.12 per share for the quarter, up from their previous estimate of $0.08. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.29 per share. Seaport Res Ptn also issued estimates for Hims & Hers Health’s Q2 2025 earnings at $0.15 EPS, Q3 2025 earnings at $0.18 EPS and Q4 2025 earnings at $0.19 EPS.

A number of other research firms have also recently weighed in on HIMS. Deutsche Bank Aktiengesellschaft lifted their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th. Leerink Partners lifted their price target on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a report on Tuesday. Truist Financial increased their price objective on shares of Hims & Hers Health from $24.00 to $39.00 and gave the stock a “hold” rating in a research note on Wednesday. TD Cowen restated a “buy” rating and set a $28.00 target price on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Finally, Morgan Stanley lowered Hims & Hers Health from an “overweight” rating to an “equal weight” rating and increased their price target for the stock from $42.00 to $60.00 in a research note on Tuesday, February 18th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $34.47.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $41.87 on Wednesday. The stock has a 50-day simple moving average of $35.89 and a two-hundred day simple moving average of $26.36. The firm has a market capitalization of $9.15 billion, a PE ratio of 95.15 and a beta of 1.35. Hims & Hers Health has a 52-week low of $11.20 and a 52-week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million.

Insider Activity at Hims & Hers Health

In related news, insider Soleil Boughton sold 4,152 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total value of $251,984.88. Following the completion of the transaction, the insider now directly owns 157,345 shares of the company’s stock, valued at approximately $9,549,268.05. This trade represents a 2.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Andrew Dudum sold 128,127 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $58.27, for a total transaction of $7,465,960.29. Following the completion of the transaction, the chief executive officer now directly owns 97,687 shares of the company’s stock, valued at approximately $5,692,221.49. This trade represents a 56.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,097,578 shares of company stock valued at $38,080,320. 17.71% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of HIMS. Main Management ETF Advisors LLC purchased a new position in Hims & Hers Health during the third quarter worth $672,000. Robeco Institutional Asset Management B.V. purchased a new position in Hims & Hers Health during the third quarter worth $604,000. Royce & Associates LP boosted its stake in Hims & Hers Health by 17.0% during the third quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock worth $6,281,000 after buying an additional 49,500 shares during the period. Versor Investments LP purchased a new position in Hims & Hers Health during the third quarter worth $634,000. Finally, International Assets Investment Management LLC purchased a new position in Hims & Hers Health during the third quarter worth $6,790,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.